A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Category: Uncategorized

  • DVT in Young Adults – IVC Abnormalities

    Stephan Moll, MD writes….. When a young person is diagnosed with extensive pelvic DVT or inferior vena cava thrombosis, there may be an underlying and predisposing congenital abnormality of the IVC, such as a congenital absence (agenesis, aplasia) or narrowing (hypoplasia) of the IVC

  • Psychological impact of DVT and PE

    Beth Waldron, Program Director of Clot Connect, writes… The patient diagnosed with VTE (venous thromboembolism) may develop depression and anxiety, particularly if the clot was extensive and life-threatening.  However, evaluation of the care and outcome of patients with VTE is often focused upon the visible short-term effects of a clot, such as:  Has the acute clotting…

  • New ACCP Guidelines – DVT and PE: Highlights and Summary

    Stephan Moll, MD writes…  This month the American College of Chest Physicians (ACCP) published its new (2012) guidelines regarding anticoagulation and management of various thrombotic disorders, replacing the 2008 edition. The details of the new guidelines can be found here

  • New ACCP Guidelines

    Quick note: New ACCP (American College of Chest Physicians) guidelines on antithrombotic therapy published today:   http://www.chestnet.org/accp.

  • How Often Should the INR be Tested?

    Stephan Moll, MD writes… Traditionally, INR testing in patients on warfarin has been recommended by anticoagulation providers in the U.S. to be done at least once every 4 weeks. However, a recent study showed that testing every 3 months is sufficient

  • INR Patient Self-Testing

    Stephan Moll, MD writes… INR testing in patients on warfarin is classically done in a physician’s office or anticoagulation clinic, via (a) i.v. blood draw and central lab testing, or (b) a finger-stick and testing on a POC (point-of-care) device. POC devices give reliable INR results

  • Xarelto and DVT – Approved in Europe

    Xarelto (Rivaroxaban) was approved in Europe today (Dec 19th, 2011) for patients with acute DVT. This is good news

  • ASH 2011: Highlights in Thrombosis and Anticoagulation

    The annual meeting of the American Society of Hematology (ASH) took place in San Diego from Dec 10-13, 2011.  Abstracts on thrombosis and anticoagulation that I found  interesting and clinically relevant  are summarized and put into a clinical perspective in this summary document.  Only one abstract was, in my assessment, clinical-practice-changing – abstract #543: “Aspirin after…